Section links:

About NIHR DeNDRoN

DeNDRoN Coordinating Centre

Key Targets 2010-2015

Leadership Structure

Governance Structure

Conferences

Contact Us

Portal Password Reset Details

Network Map

Site Map


Links

DeNDRoN Portal

NIHR CRN Co-ordinating Centre

NIHR

DeNDRoN Portfolio

NIHR Portfolio Eligibility Criteria

Industry Trials Submission Form

Alzheimer's Society

Parkinson's UK

MND Association

Huntington's Disease Association

Alzheimer's Research UK

University College London

Newcastle University

DeNDRoN: Targets for 2010-2015

The key to DeNDRoN’s success will lie in its integration in the organisations and acceptance by the individuals from which the network is composed.  The purpose of the Co-ordinating Centre and Local Research Networks is to provide the leadership and administration necessary to bring the network together; to support the integration of health research and patient care; and to co-ordinate the development of capacity and expertise within the constituent parts of the network necessary to improve the quality and speed of research they support.

Key network targets

#

Measure

Target

Aspirational target

  1.  

Active management of the network

1.1

Percentage of relevant NHS organisations referring patients to portfolio studies

20% increase on baseline

90% of all relevant NHS organisations

1.2

Percentage of relevant consultants referring to portfolio studies

20% increase on baseline

50% of all consultants

1.3

Percentage of cases consented onto the DeNDRoN RAFT (Recruitment And Feasibility Tool)

10%

30%

  1.  

Development and delivery of a balanced portfolio

2.1

Number of large scale, multicentre studies that are funded

50% increase on baseline

100% increase on baseline

2.2

Size of portfolio

20% increase on baseline

100% increase on baseline

2.3

Percentage of non-commercial studies completing on target to predefined timelines

80%

90%

2.4

Number of multi-disciplinary research sites capable of delivering complex interventional trials

20% increase on baseline

50% increase on baseline

2.5

Number of patients in non-commercial studies

100% increase on baseline

150% increase on baseline

  1.  

Meeting the needs of industry

3.1

Percentage of  studies delivered on target to predefined timelines

80%

90%

3.2

Number of commercial PIs

50% increase on baseline

100% increase on baseline

3.3

Number of patients in commercial trials

100% increase on baseline

150% increase on baseline